Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct 21:4:1165-71.
doi: 10.2147/OPTH.S6289.

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations

Emilio Rintaro Suzuki Jr  1 , Cibele Lima Belico Suzuki
Affiliations

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations

Emilio Rintaro Suzuki Jr et al. Clin Ophthalmol. .

Erratum in

  • Clin Ophthalmol. 2010;4:1277

Abstract

Travoprost is a prostaglandin analog used in the management of glaucoma and ocular hypertension for reducing intraocular pressure (IOP). The IOP-lowering efficacy of travoprost has been shown to be similar to that of other prostaglandins, including latanoprost and bimatoprost. When compared with fixed combinations of timolol and either latanoprost or dorzolamide, travoprost alone can reduce mean IOP in a similar or superior manner. Concomitant therapy of travoprost and timolol can reach even greater IOP reductions than fixed combinations at some time points, but with no difference in the early morning, when IOP is usually higher. In addition, the long duration of action of travoprost can also provide better control of IOP fluctuation, probably due to its stronger prostaglandin F receptor mechanism. The side effects of travoprost do not represent a risk to the vision or health of the patient. The proven efficacy and safety combined with convenient once-daily dosing for travoprost increases patient compliance with treatment for glaucoma.

Keywords: glaucoma; prostaglandin; travoprost.

PubMed Disclaimer

References

    1. Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844–851. - PMC - PubMed
    1. The AGIS Investigators. The advanced glaucoma intervention study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429–440. - PubMed
    1. Heijl A, Leske MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group. Reduction of IOP and glaucoma progression results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279. - PubMed
    1. Hoy SM, Keam SJ, Keating GM. Travoprost/timolol. Drugs Aging. 2006;23(7):587–597. - PubMed
    1. Rossi GC, Pasinetti GM, Scudeller L, Tinelli C, Milano G, Bianchi PE. Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination. Expert Opin Pharmacother. 2010;11(4):499–504. - PubMed

LinkOut - more resources